Singapore: Viralytics has received $1.467 million from the Australian Taxation Office for a research and development tax concession relating to the financial year to June 2012.

This is greater than the $871,000 originally estimated and published in the company's 2012 annual report.

These funds will contribute to Viralytics' oncolytic virus programs including the Phase 2 melanoma study in the US, and other potential indications including bladder cancer.